CA-CEPTON-TECHNOLOGIES
11.10.2021 15:02:06 CEST | Business Wire | Press release
Cepton Technologies, Inc., an innovative provider of smart lidar solutions , announced today its membership in the Qualcomm® Smart Cities Accelerator Program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005191/en/
The Qualcomm Smart Cities Accelerator Program brings technologies and companies together to collaborate, innovate, and accelerate the rollout of smart cities and smart connected spaces globally. Cepton believes its presence in this ecosystem aligns with Qualcomm Technologies, Inc.’s vision of bringing efficient, safe, and advanced technology to fast-growing urban environments. With its membership, Cepton aims to advance the use of lidar-based solutions with ecosystem members of the Qualcomm Smart Cities Accelerator Program across smart cities and smart connected spaces.
Through the Qualcomm® IoT Services Suite, Cepton and one of its key partners in smart spaces, The Indoor Lab, plan to collaborate with Qualcomm Technologies in offering Smart Venues as a Service , utilizing a lidar-based crowd analytics system which adheres to the privacy concerns and optimizes the utilization of spaces.
With its high-accuracy, 3D perception capabilities and 24/7 availability , lidar can enable a wide range of applications to help build safer, smarter, and better-connected environments. Thanks to their anonymized data, lidars maximize protection of people’s privacy as they collect useful information to help drive intelligent decisions in smart cities and smart spaces. Cepton has been working with global partners to enable the transformation of transportation infrastructure, public venues and large commercial facilities using smart lidar solutions. For example, Cepton’s partnership with The Indoor Lab deployed a lidar-based crowd analytics solution as a pilot project at an Orlando International Airport terminal in 2020 to offer anonymous foot fall tracking, helping maintenance crews in targeted cleaning and travelers in avoiding crowded areas.
“We are proud to join Qualcomm Technologies’ network of technology innovators through the Qualcomm Smart Cities Accelerator Program as we work to help advance the future of smart infrastructure with our lidar technologies,” said Dr. Jun Pei, CEO of Cepton. “To date, our technology has been successfully used to enable real-time traffic and pedestrian monitoring at road and rail intersections , free-flow electronic tolling systems , critical infrastructure security , and crowd analytics . By joining the Qualcomm Smart Cities Accelerator Program ecosystem, we look forward to making our technologies more accessible on a global scale.”
“Our partnership with Cepton has been invaluable to establish The Indoor Lab as a market leader for lidar-based analytics,” said Patrick Blattner, Co-Founder and Chief Product Officer of The Indoor Lab . “Last week at the 3rd Annual Qualcomm Smart Cities Accelerate Event, we were proud to showcase our solution and its wide variety of applications to the global Qualcomm Smart Cities Accelerator Program ecosystem.”
"We are pleased to welcome Cepton as a member of our cutting-edge Qualcomm Smart Cities Accelerator Program. We look forward to working together to bring cutting-edge smart lidar solutions and applications to a variety of urban environments and collaborating to offer Smart Venues as a Service through the Qualcomm® IoT Services Suite," said Sanjeet Pandit, Senior Director, Business Development, and Global Head of Smart Cities, Qualcomm Technologies, Inc.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Smart Cities Accelerator Program is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.
Qualcomm IoT Services Suite is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005191/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
